


Outsourcing buzz in Indian biotech bay

12 April 2004 | News



According to a report on clinical research by the Confedera tion of Indian Industry (CII), the contract research service market is estimated to be around \$9 billion. "There is an increased global trend towards collaborative outsourcing," the CII report says. The global outsourcing pre-clinical work and clinical research accounts for nearly \$13 billion.

Human Genome Inc eager to foray in India
But more importantly, according to Proximare Inc, a business consultant for pharma, biotech and related companies, over FRANCE AND INTERIOR SET OF THE BEAUTH PROPERTY OF THE PROPERTY Photon Carther Slobal Partnering Summit organized by Frost & Sullivan

in New Delhi this month. Dr William A Haseltine, founder and CEO,
Huhere are around a dozen of pipiotech and pharma companies that are considering outsourcing their work to India through
huhere are around a dozen of pipiotech and pharma companies that are considering outsourcing their work to India through
work object of the Indian pharmaceutical his cap become object of the Indian companies to explore their
dimensions by loading of present scenario war cap predict that around \$200 million work in pharma and related areas is
likely to be outsourced to India in the next 12 months, "said Nailesh A Bhatt, managing director, Proximare. "The companies <mark>ାଦ୍ୟଧ୍ୟୟ ଓଡ଼େ ମଧ୍ୟ କ୍ରମ୍ୟକ୍ତ ଆଧ୍ୟ ବର୍ଷ ବର୍ଷ ନ</mark>୍ତି <mark>। ଜଣ୍ଡି ନେ ଆଧିନ ନ୍ଧୁ ହିନ୍ଦି ଆଧିନ ବର୍ଷ କ୍ରମ୍ୟ କ୍ରମ୍ୟ କ୍ରମ୍ୟକ୍ତ ଆଧିନ ବର୍ଷ ବର୍ଷ କ୍ରମ୍ୟ କ୍ରମ୍ୟକ୍ତ ଆଧିନ ବର୍ଷ କ୍ରମ୍ୟକ୍ତ କ୍ରମ୍ୟକ୍ତ । he added.</mark>

biotechnology industry here offers immense opportunities for the protectionology industry here offers immense opportunities for the according to Kiran Mazumdar Shaw chairpers of an and managing director. Biocon, the biotechnology industry in India holds a spiritual weight of the country of the presence of a director, and the biotechnology industry in India holds a spiritual industry of the presence of the present the presence of the present the p As welling the market for ever an oracle at a properties and diagnostics, but also as an international hub for prominents where there is abblact with a strengthers it in large

quantity. Few people are aware that venture capital investment in the More and more pharmace that venture capital investment in the More and pharmace thical and life sciences companies are adopting complex networking, collaborative and outsourcing strategies in order in blend cost efficiencies with maximized innovation in the drug development cycle. Indian contract research organizations are becoming major players in this billion-dollar industry. This is one of the main reasons for the leaders of a research organization in the live "World Economic Forum" to incorporate a horse exception of the main reasons for the leaders of a research organization. leaders of a renowned forum like "World Economic Forum" to incorporate pharmaceutical outsourcing subject into their

99670 bean companies from France, Sweden, among others, form the backbone of capital investment in the US biotech industry and the same Since 1986 the World Economic Farting and the Confederation of Indian Industry (CII) have held a yearly India Economic Farting and the Confederation of Indian Industry (CII) have held a yearly India Economic Farting and the Confederation of Indian Industry (CII) have held a yearly India Economic Farting and the Confederation of Indian Industry (CII) have held a yearly India Economic Farting and the Confederation of Indian In discovered using our genomics-based technology."

Ebe list of companies considering outsourcing work to India include small to mid-sized pharma companies and biotech Companies besides malor pharma companies as marketing genebased drugs to treat and cure disease. It has nine products in clinical some of Proximate's clients include Merck, Bristol-Myers, Soulbb, Warner-Lambert, Colgate-Palmolive, Sumitomo, development, including drugs to treat such diseases as cancer on setting up research and development (R&D) work in India," the products in clinical warner-Lambert, Colgate-Palmolive, Sumitomo, development (R&D) work in India," the products in clinical warner-Lambert, Colgate-Palmolive, Sumitomo, development (R&D) work in India," Bhatt said.

The high quality knowledge base and low infrastructure costs are some of the key attractions of Indian biotech industry for the global audience. But it is time to understand India's own skill set for its development. Actually, it is a crucial aspect for drivers of the India's biotech ship.

Faiz Askari